Research Topics
| Suzie J OttoSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate CancerSuzie J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Int J Cancer 105:394-9. 2003..Although the reasons for ordering PSA test or indicating biopsy are unknown, effective PSA contamination in the Rotterdam ERSPC section is low and not likely to jeopardize the power of the trial...
Mammography screening and risk of breast cancer death: a population-based case-control studySuzie J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P O Box 2040, Rotterdam 3000 CA, The Netherlands
Cancer Epidemiol Biomarkers Prev 21:66-73. 2012..Using individual data of women invited to screening, we conducted a case-control study to assess the effectiveness of the Dutch population-based program of mammography screening...- PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate CancerS J Otto
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Eur J Cancer 46:3053-60. 2010..To describe the variation in PSA level by age group and screening round in the ERSPC centres and the variation in cancer detection rates in relation to the underlying prostate cancer incidence... - Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?S J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Eur J Cancer 46:3061-7. 2010.... - Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trialSuzie J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
J Clin Oncol 24:4184-9. 2006.... - Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?S J Otto
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
J Med Screen 11:89-92. 2004..In addition, the accuracy of the randomisation was evaluated by comparison amongst the trial arms... - Update on screening and early detection of prostate cancerSuzie J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Curr Opin Urol 14:151-6. 2004..The aim of this review is to discuss advances in the field of screening and early detection of prostate cancer from papers published in 2003... - Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-upXiaoye Zhu
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 60:330-6. 2011..In a screening program, interval cancers are cancers diagnosed between two screening visits... 
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-RotterdamElisabeth M Wever
Department of Public Health, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Natl Cancer Inst 102:352-5. 2010..26 in the United States vs 0.94 in ERSPC-Rotterdam. We conclude that the efficacy of PSA screening in detecting prostate cancer was lower in the United States than in ERSPC-Rotterdam...- Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate CancerGerrit Draisma
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Natl Cancer Inst 95:868-78. 2003..Both consequences have considerable impact on the net benefits of screening... - Increased non-prostate cancer death risk in clinically diagnosed prostate cancerPim J van Leeuwen
Department of Urology Public Health, Erasmus Medical Centre, Rotterdam Cancer Registry Rotterdam, Rotterdam, The Netherlands
BJU Int 110:188-94. 2012..Men with clinically diagnosed PC have an increased risk of death unrelated to PC itself, i.e., the excess mortality is based on an increased risk of dying from other neoplasm and diseases of the circulatory or respiratory system... - Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic reviewSuzie J Otto
Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, Netherlands
Lancet 361:1411-7. 2003..INTERPRETATION: Routine mammography screening can reduce breast-cancer mortality rates in women aged 55-74 years... - Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trialBart Klijs
Department of Public Health, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, Netherlands
BMC Public Health 12:671. 2012..We describe the design and present the results of the first year of a population-based study of screening for type 2 diabetes in individuals at high risk of developing the disease. High risk is defined as having abdominal obesity... - Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trialStijn Roemeling
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Prostate 67:1053-60. 2007..We present a feasibility study and impact simulation of a secondary analysis, which imitates a situation where all participants in the study are managed according to their random assignment... - Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohortAndre N Vis
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
Eur Urol 53:91-8. 2008..Overall survival in both cohorts was compared with that in the general population... - Quality-of-life effects of prostate-specific antigen screeningEveline A M Heijnsdijk
Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
N Engl J Med 367:595-605. 2012..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain... - Limited contamination in the Dutch-Belgian randomized lung cancer screening trial (NELSON)Eleonora Baecke
Department of Public Health, Erasmus MC University Medical Center Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Lung Cancer 69:66-70. 2010..In conclusion, the rate of contamination among male subjects of the control arm of the NELSON trial is low and is not likely to jeopardize the power of the trial... - Decreased rates of advanced breast cancer due to mammography screening in The NetherlandsJ Fracheboud
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 1753, NL 3000 DR Rotterdam, The Netherlands
Br J Cancer 91:861-7. 2004..It is evident that breast cancer screening contributes to a reduction in advanced breast cancers and breast cancer mortality... - Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006Johannes D M Otten
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Cancer 123:1929-34. 2008..The results indicate an impressive decrease in breast cancer mortality in the age group invited for breast cancer screening, starting to show quite soon after implementation...